Dissecting multiple roles of SUMOylation in prostate cancer. (28th November 2021)

• Record Type: Journal Article
• Authors: Wang, Yishu; Yu, Jianxiu
• Is Part Of: Cancer letters. Volume 521(2021)
• Page Start: 88
• Page End: 97
• Publication Date: 2021-11-28
• Subjects: Prostate cancer (PCa) -- SUMOs -- SUMOylation -- Therapeutic intervention; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2021.08.034
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Protein modification with small ubiquitin-like modifiers (SUMOs) plays dual roles in prostate cancer (PCa) tumorigenesis and development. Any intermediary of the SUMO conjugation cycle going awry may forfeit the balance between tumorigenic potential and anticancer effects. Deregulated SUMOylation on the androgen receptor and oncoproteins also takes part in this pathological process, as exemplified by STAT3/NF-κB and tumor suppressors such as PTEN and p53. Here, we outline recent developments and discoveries of SUMOylation in PCa and present an overview of its multiple roles in PCa tumorigenesis/promotion and suppression, while elucidating its potential as a therapeutic target for PCa. Highlights: The dual opposing roles of SUMOylation in prostate cancer (PCa). The aberrant expression of SUMO machinery components and deregulation of related signaling pathways occurs in PCa. Altered SUMOylation of oncoproteins is involved in the initiation and progression as well as inhibition of PCa. SUMOylation of tumor suppressors including p53 and PTEN regulates tumorigenesis and development of PCa. SUMOylation is an emerging target for therapeutic interventions of PCa.